Lupin receives approval from U.S. FDA for Diazepam Rectal Gel
Lupin Limited's subsidiary, Novel Laboratories Inc., based in Somerset, New Jersey, has received approval from the U.S. FDA for its Abbreviated New Drug Application for Diazepam Rectal Gel, 10 mg and 20 mg, Rectal Delivery System.
Source: equitybulls.com